A new venture from Mayo Clinic and Thermo Fisher Scientific highlights how clinical laboratory capabilities can support businesses that combine testing, patient data, and diagnostic development.
Mayo Clinic announced the launch of Precure, LLC on Sept. 15. The company plans to combine molecular data from one million biospecimens with clinical information collected over several years to investigate biological changes that occur before disease symptoms appear. Mayo is the majority owner; Thermo Fisher holds a minority stake.
The effort will integrate genomic and protein data, using artificial intelligence and large-scale analytics to identify patterns that could support new diagnostics and treatments. Thermo Fisher will contribute proteomics technology, mass spectrometry, kits, and reagents, while Mayo supplies clinical expertise, biospecimens, and de-identified patient information.
In August, we reported that at the Association for Diagnostics & Laboratory Medicine (ADLM) annual meeting mass spectrometry garnered tons of attention, as in vitro diagnostics companies heavily promoted the technology.
Helix brings clinical laboratory capabilities
In one of its first moves as a company, Precure named Helix its laboratory and AI tools provider on Sept. 21. Helix will provide clinical whole genome sequencing, research-grade protein analysis, and tools intended to help integrate genomic information into clinical care. The collaboration draws on Helix’s CLIA-certified sequencing capabilities, workflow management, and data infrastructure.
“Our goal is to generate genomic information that can help inform patient care while creating a powerful resource for discovery,” said Aaron Mangold, MD, Precure’s chief medical officer, in Mayo’s announcement.
For clinical laboratory leaders, the partnership suggests a business opportunity worth watching: supplying the testing expertise and infrastructure that connect health systems with diagnostic developers. Helix’s role illustrates how a laboratory partner can contribute sequencing, data management, and support for clinical integration.
However, generating a large dataset is an early step. Mayo describes Precure as infrastructure for discovery and collaboration, with clinical validation needed to translate findings into patient care. The venture’s progress could offer laboratory leaders insight into how such partnerships move from research to clinically useful tests.
This article was created with the assistance of Generative AI and has undergone editorial review before publishing.





